Listen to our latest interactive webinar to hear from four experts as they discuss the factors that can influence a company’s manufacturing business model including:
- What impact your manufacturing strategy has on the valuation of your business?
- How critical is the decision to outsource or build out from an investor perspective?
- How important a consideration is manufacturing when building your business strategy and deciding on disease indications?
- What impact might automation have on the decision to outsource or build in-house?
Moderated by industry expert, Barbara Nelsen of Nelsen Biomedical, the webinar will feature an experienced panel:
Dr Kim Warren, AVROBIO, USA
Dr Aaron Dulgar-Tulloch, GE Healthcare/CCRM, Canada
Patrick Rivers, Aquilo Capital, USA
By registering to view this On Demand Webinar you are also signing up as a member of Cell & Gene Therapy Insights and agree to be contacted by Cell & Gene Therapy Insights' sponsors. We will email you a username and password so you can read all our open access content.
Dr Barbara Nelsen
Founder and CEO, Nelsen Biomedical
Barbara Nelsen is the founder of Nelsen Biomedical. She brings more than 20 years of experience in R&S, business and strategic development within the life sciences industry. Barbara has extensive experience in moving technology from concept to commercialization, developing business models, implementing business plans and creating strategic partnerships and market expansion activities. Barbara has truly sat on all sides of the table. She has been an investor (Sofia Fund, Northern Lights Seed Fund), and a scientific investigator (Brandeis University, the Whitehead Institute). She has worked in the industry in both research and development (Director, Cancer Therapeutics and Diagnostics Institute, Australia) and in business development (MGI Pharma). She uses her broad experience, deep expertise and extensive networks to create success for her clients. Barbara holds both a PhD in molecular biology and an MBA.
Dr Kim Warren
Head of Operations, Avrobio
Kim is an experienced scientist with entrepreneurial and business management experience in cell therapy. She spent the last 10 years at Lonza, developing a services business, including tissue acquisition, process development, bioassays and related services to support GMP manufacturing of cellular therapeutics. Kim also headed R&D at Cambrex, developing cell-based research products. She founded and ran Poietic Technologies, acquired by Cambrex in 1999. She has also held research positions in pharma (Otsuka) and biotech (Cetus). Kim has a Ph.D. in Comparative Physiology from University of Maryland and postdoctoral training in Immunology at USUHS, Bethesda MD.
Dr Aaron Dulgar-Tulloch
Director, BridGE at GE Healthcare
Aaron helped found and currently directs BridGE@CCRM for GE Healthcare Cell Therapy Technologies. BridGE@CCRM is a $40M GE collaboration with the Centre for Commercialization of Regenerative Medicine (CCRM) and the Government of Canada to create a Centre for Advanced Therapeutic Cell Technologies to offer technology and process development services for cell and gene therapy manufacturers. Prior to his current role, Aaron oversaw Research and Portfolio Management for the cell therapy division of GE and has previously served in a variety of management and scientific positions within GE Healthcare and GE Global Research. Aaron earned his Ph.D. in Materials Science and Engineering from Rensselaer Polytechnic Institute focusing on tissue engineering and mesenchymal stem cells and his Bachelor of Science in Engineering in Chemical and Biological Engineering from Princeton University.
Patrick joined Aquilo Capital in 2014. From 2005-2014 he worked as a research scientist in various drug development capacities for several public and private biotech firms, including Sutro Biopharma, Exelixis and Xoma. This experience includes research and development for preclinical and clinical stage products in oncology and inflammatory diseases. Patrick received his B.S. in Chemical Engineering at UCLA and his MBA from UC Berkeley’s Haas School of Business.